Vaccine research and development are experiencing a renaissance of interest from the global scientific community. There are four major reasons for this: (1) the lack of efficacious treatment for many devastating infections; (2) the emergence of multidrug resistant bacteria; (3) the need for improving the safety of the more traditional licensed vaccines; and finally, (4) the great promise for innovative vaccine design and research with convergence of omics sciences, such as genomics, proteomics, immunomics, and vaccinology. Our first project based on omics was initiated in 2000 and was termed reverse vaccinology. At that time, antigen identification was mainly based on bioinformatic analysis of a singular genome. Since then, omics-guided approaches have been applied to its full potential in several proof-of-concept studies in the industry, with the first reverse vaccinology-derived vaccine now in late stage clinical trials and several vaccines developed by omics in preclinical studies. In the meantime, vaccine discovery and development has been further improved with the support of proteomics, functional genomics, comparative genomics, structural biology, and most recently vaccinomics. We illustrate in this review how omics biotechnologies and integrative biology are expected to accelerate the identification of vaccine candidates against difficult pathogens for which traditional vaccine development has thus far been failing, and how research will provide safer vaccines and improved formulations for immunocompromised patients in the near future. Finally, we present a discussion to situate omics-guided rational vaccine design in the broader context of global public health and how it can benefit citizens in both developed and developing countries.
Introduction
V accines are one of the most effective and sustainable ways of preventing infectious diseases. Vaccines against diphtheria, tetanus, polio, measles, mumps, rubella, pneumococcus, hepatitis B, and meningitis (Haemophilus influenzae and serogroup C meningococcus) have reduced the incidence and mortality of these diseases by >97-99% (Rappuoli et al., 2002) . The history of vaccines and immunization began with the landmark 1796 cowpox experiment of Edward Jenner in which he demonstrated that a boy inoculated with pus from a milkmaid's hand lesion was subsequently protected against smallpox infection. These findings led to the formulation of the vaccine concept. Jenner's work was further refined by Louis Pasteur in the 19th century. Pasteur is credited with a great milestone in vaccine research: his hallmark development of rabies vaccine in 1885, the first human vaccine created in the laboratory. Ever since, scientists have focused on vaccination as the best defense against numerous bacterial and viral pathogens. The principles established by Louis Pasteur, that is, isolation, inactivation, and administration of disease causing microbes, have guided vaccine development throughout the 20th century.
The overall vaccine research and developmental approach can be broadly categorized into three generations: (1) the ''first generation'' of vaccine development was essentially based on the basic principles of Pasteur, which consist of using inactivated pathogens in whole or live attenuated forms as vaccine [e.g., Bacillus Calmette Guerin (BCG), plague, pertussis, polio, rabies, and smallpox] (Kaushik and Sehgal, 2008; Rappuoli et al., 2002) ; (2) the ''second generation'' vaccines made up of purified microbial cell components (referred as subunit vaccines, e.g., polysaccharides, or protein antigens such as those used against tetanus, diphtheria, anthrax, pneumonia, influenza, hepatitis B, and lyme disease) (Plotkin, 2005) . This approach has more recently exploited recombinant DNA technology and polysaccharide chemistry.
Despite the fact that traditionally developed vaccines were pivotal in controlling or eradicating many deadly diseases like smallpox, polio, pertussis, and tetanus during the last century, these conventional empiric methods of vaccine design have shown severe limitations: (1) they cannot be applied to microbes that are noncultivable in vitro (e.g., hepatitis C, papilloma virus types 16 and 18, and Mycobacterium leprae); (2) they often fail to provide widely protective vaccines for antigenically hypervariable pathogens (e.g., serogroup B meningococcus, gonococcus, malaria, and HIV) (Rappuoli, 2004) ; (3) they have failed to adapt to opportunistic pathogens, e.g., Staphylococcus aureus (Projan et al., 2006) ; (4) they have been slow to address rapidly evolving pathogens like HIV; and last but not least, (5) these traditional approaches of vaccine development can be very time consuming and inefficient.
The enormous amount of information generated by whole genome sequencing projects and the rise of bioinformatics has triggered the birth of a new era of vaccine research and development, leading to a ''third generation'' of vaccines, which are discovered and developed by the rationale application of omics science to vaccinology (Table 1 and Fig. 1 ). The first example of such an approach is reverse vaccinology (Pizza et al., 2000; Rappuoli, 2000) . An omics is a neologism referring to the study of all constituents considered collectively. For example, genomics determines the entire DNA sequence of organisms, whereas proteomics studies the entire complement of proteins. The related suffix ''ome'' is the object of study of the field such as the genome or proteome. It is intuitive to understand then, why omics became so important for vaccine discovery. The availability of all the genes and expressed proteins of a microorganism perfectly fits with the need to develop safer and better characterized subunit vaccines. In the present review we provide an overview of how all the omics can now be integrated to further advance vaccine research and development. The first part of the review describes genomics-driven antigen selection. Genomics was the first omics used in vaccinology (with the reverse vaccinology approach). Initially the study was based on the genome of one strain only, then, with the advent of high-throughput sequencing and the public availability of multiple genomes of the same species, comparative genomics and pan-genomics were included among the vaccine discovery omics. A role complementary to the genomic sciences mentioned so far is played by functional genomics, which is able to provide important information regarding the function and dynamics aspects of genes through mutagenesis and transcription analysis. In the second part, we have described proteomics-based antigen discovery, which is able to identify actually surface exposed and secreted proteins. This technology takes advantage of the power of mass spectrometry and two-dimensional gel electrophoresis (2DE). In the same section we have also summarized how structural biology can be used to instruct the identification of exposed epitopes of the antigens and improve vaccine design. The third part includes immunomics-based antigen identification strategies, such as antigenomics and protein microarray, which are important to understand if antigens selected by in silico and in vitro approaches are potentially immunogenic in humans. In the last part, we emphasized the role of vaccinomics, improved protein purification techniques, adjuvant discovery, and regulatory authorities in the generation of safer and tailored vaccines. The different approaches described in the review present advantages and limitations and only from a balanced integration of the information originating from them can truly rationale vaccine design be born.
Part 1: Genomics-Based Antigen Selection Approaches
Genomics was the first omics applied to vaccine discovery By controlling debilitating and often lethal infectious diseases, vaccines have had an enormous impact on global public health (Rappuoli, 2004) and with the arrival of the genomics era, a paradigm shift has occurred in the development of vaccines providing a new impetus to this field (Bambini and Rappuoli, 2009) .
Since the completion of the first bacterial genome sequence of Haemophilus influenzae in 1995 (Fleischmann et al., 1995) , advances in sequencing technology and bioinformatics have resulted in an exponential growth of genome sequence information. More than one genome sequence is now available for each major human pathogen, and by August 2010, over 1,300 bacterial genome sequences had been completed (i.e., closed genomes and whole genome shotgun sequences) with more than 4,800 ongoing and over 2,400 viral genomes completed (http://www.genomesonline.org/cgi-bin/GOLD/bin/ gold.cgi, http://www.ncbi.nlm.nih.gov/genomes/Genomes Home.cgi?taxid ¼ 10239).
Having made available collective genetic material of entire organisms as a whole, genomics has changed the landscape of modern biology providing access to entire gene/pseudogene repertoires, facilitating our understanding of gene networks, revealing genomic diversity and genome evolutionary dynamics. Novel bioinformatic tools, coupled with the exponentially growing number of bacterial genome sequencing projects, have revolutionized our understanding of the prokaryotic world. Computational biology can circumvent conventional time-consuming and laborious experimental techniques and facilitate proceeding directly from gene sequencing to protein functional assignments and as a consequence, from genome sequence to functional genomics (Fraser et al., 2000) . The complete sequence of a bacterial genome also provides a new opportunity to tackle vaccine development. Without the need to cultivate pathogens and identify antigens using biochemical techniques, all the protein antigens are equally visible at once within an annotated genome, regardless of their in vitro and in vivo expression pattern. This allows the identification not only of all the antigens selected using the conventional biochemical, serological, and microbiological methods but also the discovery of novel antigens (Rappuoli, 2001) .
Genomic databases generally contain not only whole genome sequences but also the complete repertoire of proteins encoded by the genomes from which vaccine screening is possible. When genomic sequences appear before their completion, it is necessary to perform a gene finding analysis. This is accomplished by prediction algorithms, which scan the sequence in search of regions that are likely to encode proteins. One of the most commonly used is Glimmer (Table 2) , a software package for predicting genes in microbial DNA, identifying the coding regions, and distinguishing from noncoding DNA. Genome visualization is possible through bioinformatic tools such as Artemis (Table 2) , a free genome viewer and annotation tool that allows visualization of sequence features and also its six-frame translation.
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BAGNOLI ET AL. Ariel et al., 2002; Bergman et al., 2007; Chitlaru et al., 2007; Klee et al., 2010; Read et al., 2002 Read et al., , 2003 Bordetella pertussis
Whooping cough, pertussis
Proteomics, immunoproteomics D (Altindis et al., 2009; Vidakovics et al., 2007; Williamson et al., 2010) Burkholderia mallei, pseudomallei, and cenocepacia
Glanders and melioidosis, severe respiratory infection
Genomics, functional genomics, proteomics D/P (Chong et al., 2006; Felgner et al., 2009; Mariappan et al., 2010; Sarkar-Tyson and Titball, 2010) Chlamydia pneumoniae 
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Antibiotic-associated diarrhoea Proteomics, comparative genomics D/P (Pechine et al., 2007; Stabler et al., 2009; Wright et al., 2005 Wright et al., , 2008 E. coli (pathogenic) Urinary tract infections diarrhea, hemolytic-uremic syndrome Reverse vaccinology, comparative genomics, Proteomics, immunoproteomics D/P (Durant et al., 2007; Moriel et al., 2010; Sommer et al., 2010; Wieser et al., 2010) Helicobacter pylori Ulcer, gastritis, adenocarcinoma, lymphoma
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Acute pneumonia
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Listeria monocytogenes
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Comparative genomics, proteomics D/P (Reis et al., 2010; Trost et al., 2005) Mycobacterium tuberculosis
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Functional genomics, proteomics D/P (Chaudhuri et al., 2008; Crompton et al., 2010; Doolan et al., 2008; Singh et al., 2010) B. 
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Brucella abortus
Comparative genomics and pan-genomics
In the genomic-based selection of vaccine candidates, comparative genomics and pan-genomics play a major role as they allow a deeper comprehension of intraspecies and interspecies antigen variability and distribution (Medini et al., 2005) . Interspecies analysis is particularly important as it can identify and discard antigens that show high similarity with genes present in bacteria of the human flora. Therefore, this analysis prevents undesirable crossreaction of vaccineelicited antibodies against known benign, commensal species. The most optimal protein vaccine candidates are unlikely to be found conserved across genomes as they are for the most part exposed by the pathogen to the host immune system during infection and therefore under strong selective pressure.
Antigen conservation among different pathogen strains and serotypes was taken into account to formulate a widely protective vaccine for group B Streptococcus (GBS), which, as with many other bacterial pathogens, adopts the strategy of gene variability to escape the immune system (Maione et al., 2005) . As universal protective protein antigens are unlikely to exist, some protein antigens may be conserved in sufficiently large subpopulations that in combination they can be broadly protective, as in the GBS (Margarit et al., 2009 ) and the Neisseria meningitidis serogroup B (MenB) (Giuliani et al., 2006; Lucidarme et al., 2009) vaccines. Fortunately, not every bacterial species has the same level of complexity as GBS or N. meningitidis (Medini et al., 2005 (Medini et al., , 2008 .
Another criterion is the selection of noncrossreactive antigens in nonpathogenic commensal strains. Antigens that are specific to pathogenic strains are selected as putatively correlating with virulence. For example, completion of the genome sequence of Escherichia coli O157:H7 (virulent strain) revealed that this strain possesses >1,300 strain-specific genes compared with the E. coli K12 commensal strain; these genes encode proteins that are involved in virulence and metabolic capabilities (Perna et al., 2001) . Moreover, when the genomes of three E. coli strains (K12, O157:H7 and the uropathogenic strain CFT073) were compared, only 39.2% of genes could be found in all three strains (Welch et al., 2002) . These kinds of analyses can provide the information necessary for the identification of virulence factors. From a vaccine point of view, genes encoding antigens conserved in both pathogenic and nonpathogenic strains could be discarded during the selection, reducing the number of candidates to express and test in the animal model and, consequently, reducing the time for delivery of a vaccine. Furthermore, selection of antigens present only in pathogenic strains might reduce the impact on the commensal flora, especially for microorganisms that possess both phenotypes, such as E. coli.
Several software have been studied for comparative genomics analyses (Table 2) including Mauve, which can construct multiple genome alignments showing large-scale changes such as gene loss, duplication, rearrangement, and horizontal transfer, or Sybil a Web-based software package for comparative genomic visualizations.
FIG. 1.
Omics and vaccine discovery. Schematic overview of the way in which omics are applied to identify vaccine candidates. Vaccine candidates can be identified by analysis of the pathogen's genome and/or pan-genome (the complete genetic content of the organism/species), transcriptome (the complete set of RNA transcripts), surfome (the complete set of expressed surface proteins), or secretome (the complete set of expressed secreted proteins), immunomics (the set of antigens that are recognized by the human or animal host), and vaccinomics (human responses to a vaccine). Finally, structural biology is expected to provide the first information to build prediction methods to identify protective epitopes. Besides specific comparative genomic analysis software it is still useful to perform all-against-all gene/protein comparative analysis by basic sequence similarity searches: sequence similarity algorithms allow comparison of predicted coding sequences (ORFs) with known genes/proteins in public databases, and are commonly used to speculate about protein function as well as gene/protein conservation in the bacterial population. Common sequence similarity tools are BLAST (Basic Local Alignment Search Tool) (Table 2 ) and the FASTA programs (Table 2 ). Both algorithms can be used to infer functional and evolutionary relationships between sequences as well as to help identify members of gene families.
In silico analysis in protein vaccine discovery
Comparative genomics provides important information about antigen distribution and conservation; however, it misses most critical features of vaccine candidates such as antigen subcellular localization. In order to identify vaccine candidates in genomic sequences, a revolutionary approach was established that stems from the assumption that surface as well as secreted proteins are more easily accessible to antibodies and therefore represent ideal vaccine candidates. The approach, termed reverse vaccinology, uses several bioinformatics algorithms to predict antigen localization. In subcellular localization prediction (SLP) the ensemble of putative proteins selected by genomic-based approaches is processed with dedicated software to deduce their putative cellular localization (Table 2) . Several computer programs are available to search for gene products with a subcellular localization spanning from the cytoplasm to the cell wall (in Grampositive bacteria) and to the outer membrane (in Gramnegative bacteria), according to their specific structures and signatures related to secreted or surface proteins (e.g., secretory leader sequences, trans-membrane helices, cell wall anchor motifs for Gram-positive bacteria). PSORT.org (Table  2 ) provides links to the PSORT family of programs for subcellular localization prediction as well as other datasets and resources relevant to localization prediction, but a successful SLP analysis may need the use of several programs (Table 2) and comparison of output data. Together with automated algorithms, it is useful to perform a direct ad oculum analysis of amino acid sequences in order to recognize simple localization signals such as leader peptide sequences and LPxTG motifs and other localization signals in cases of particularly interesting proteins or dubious (low confidence) ones (Tjalsma et al., 2000 (Tjalsma et al., , 2004 .
Although a large majority of proteins can be associated with a specific subcellular localization through localization predictors, some others require further studies. Sequence similarity searches (Table 2 ) represent a good complementary tool to analyze these proteins to study their putative localization. As already mentioned, sequence similarity searches that compare predicted coding sequences with known genes/proteins in public databases, are commonly used to speculate protein function, and thus subcellular localization can be inferred.
In silico analysis may also allow of enhanced protein antigen qualities such as expression and solubility. As native gene sequences retain their own specific codon usage that reflects the composition of their respective genomic tRNA pools, gene sequences may be optimized for higher expression levels in any heterologous system. Several algorithms (Table 2 ) are able to maximize protein expression by translating the codon usage of the native antigen sequence into the specific codon usage of the heterologous host used for cloning and expression (usually fast-growing microorganisms like E. coli or Saccharomyces cerevisiae).
Enhancing protein solubility is a delicate process unique for each antigen and is usually performed by eliminating all motifs that allow the transport across the native organism membrane(s) (such as bacterial leader peptides) and/or anchoring of the proteins on the native organism surfaces (such as LPxTG motifs in Gram-positive bacteria).
Transcriptomics
Whole genome expression profiling by measuring mRNA levels provides important biological insights. DNA microarray technology is particularly attractive for the analysis of relatively simple transcriptomes, as in the case of bacteria. In fact, DNA chips carrying entire bacterial genomes can be easily prepared. The identification of genes expressed upon infection or in response to particular factors and nutrients can be useful for the vaccine selection process for several reasons. First, it provides evidence that a gene is actually expressed. Indeed, virulence factors may not be expressed in standard culture conditions, and antigens specifically expressed during pathogenesis are generally considered promising vaccine candidates. Furthermore, antibodies generated against virulence factors, in addition to potentially mediating the killing of the pathogen, may directly inhibit its virulence mechanisms. By targeting virulence factors, a vaccine may be specifically targeted against pathogenic rather than commensal variants. Pioneering work on host-pathogen interaction based on the DNA-microarray technology has been done in the laboratory of Stanley Falkow. For example, his team has identified the expression of certain virulence factors of Helicobacter pylori after infection of colonic human cells (El-Etr et al., 2004) . However, one of the first applications of the technology in vaccinology, was to study gene regulation after interaction of Neisseira meningitidis to cultured human epithelial cells (Grifantini et al., 2002) . The authors found several genes either up-or downregulated upon contact with the host cell. In particular, 12 adhesins were identified, and 5 were able to induce bactericidal antibodies in mice.
Mycobacterium tuberculosis is one of the most thoroughly analyzed bacterial pathogens using DNA microarrays. In particular, transcriptomics has become an important tool in gaining an increased understanding of the biology of this pathogen and offers the promise of being able to deliver novel drug targets and vaccine candidates. Heat-shock proteins are among the most promising vaccine antigen candidates against TB, and the transcriptomic analysis of the heat-shock response applied by Stewart et al. (2002) has identified additional vaccine candidates.
During lung infection, M. tuberculosis resides within macrophages thereby subverting the bactericidal mechanisms of these professional phagocytes. Comprehension of this hostpathogen relationship is fundamental for the development of new therapies to cure and prevent tuberculosis. With this aim microarrays have been used to analyze the global transcriptional response of M. tuberculosis to low pH in vitro, which mimics an environmental signal encountered by phagocytosed mycobacteria (Fisher et al., 2002) , and more recently, the transcriptional profile of M. tuberculosis infecting human macrophage-like THP-1 cells (Fontan et al., 2008) . For Streptococcus pneumoniae, DNA microarray analysis has been useful for the comprehension of the bacterial global transcriptional response during different stages of infection (e.g., Song et al. , 2009 ) and within human lung epithelial cells (Song et al., 2008b) . In the latter study, Song et al. compared the transcriptome of an encapsulated pathogenic strain with that of an unencapsulated, avirulent strain during association with lung cells, and discovered differential gene expression in Streptococcus pneumoniae, thus identifying genes involved in pneumococcal pathogenesis (Song et al., 2008b) .
Functional genomics
Many functional genomics approaches have been commonly used to identify virulence genes induced during infection and likely to be good candidates for vaccines. Some of them, including signature-tagged mutagenesis (STM) and transposon site hybridization (TraSH), are based on the use of transposon mutagenesis techniques to inactivate genes of a particular pathogen, allowing the identification of genes essential for growth or infectivity.
Since 1995, when David Holden developed the STM, this technique has been successfully used to discover virulence genes from a large group of different pathogens, including: meningococcal serogroup B (MenB), where starting from 2,850 insertional mutants, 65 novel genes essential for septicemic infection in an infant rat model were identified (Sun et al., 2000) ; Staphylococcus aureus, where numerous genetic loci affecting growth and survival in four complementary animal infection models including mouse abscess, bacteremia, and wound and rabbit endocarditis were identified (Coulter et al., 1998) , and Helicobacter pylori, where a set of previously unknown colonization factors were identified (Kavermann et al., 2003) .
TraSH, which combines transposon mutagenesis and microarray hybridization, allows the analysis of much larger mutant pools than STM. Rubin and colleagues used TraSH to investigate the genetic requirements of M. tuberculosis for growth in vivo, which helped define the ''survivasome'' of this pathogen.
In vivo expression technology (IVET) and the later recombinase-based in vivo expression technology (RIVET) version are alternative gene-expression techniques designed to identify bacterial genes that are induced when a pathogen infects its host. In particular, RIVET has been used to identify ivi genes in Vibrio cholerae (Camilli and Mekalanos, 1995) and to S. aureus with the identification of 45 staphylococcal genes, of which only six were known previously, induced during infection in a murine renal abscess model (Lowe et al., 1998) .
Part 2: Proteomics-Based Antigen Selection Approaches
Surfome and secretome Development of cell fractionation procedures, mass spectrometers, analytical software, and publication of microbial genomes have resulted in a quantum leap for the application of proteomics to vaccine discovery. Proteomics, is of critical importance for vaccine research because it investigates the actual protein expression in living cells and is not based on predictive assumptions as in silico analysis. New proteomics techniques can identify surface proteins and discriminate them from cytoplasmic ones. Such data play an essential role in vaccine candidate selection because they can indicate which antigens are more exposed on the bacterial surface and hence accessible to the immune system. The first protocol developed to ''visualize'' the surface proteome of a microorganism was based on biotin labeling of viable Leptospira spp. cells and affinity capture of the biotinylated proteins (Cullen et al., 2005) . The authors named the collection of identified proteins the ''surfaceome.'' Samples were then analyzed by bidimensional electrophoresies (2-DE) and identified by mass spectrometry (MS) and matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry (MALDI TOF MS). Unfortunately, many membrane-associated proteins are hydrophobic and difficult to study by this method. Subsequently, a new technique (2-DLC-MS/MS) was introduced, which overcomes some of the problems associated with 2-DE . This gel-free method is based on 2D liquid chromatography (2-DLC) that involves strong cation exchange in the first dimension followed by reverse-phase chromatography in the second dimension, and tandem mass spectrometry (MS/MS) to separate and identify peptides that have been generated from protease digestion of complex protein mixture. The 2-DLC-MS/MS approach performs better than 2-DE analysis in processing proteins that are highly hydrophobic or highly basic, poorly expressed, with high molecular weight, and/or with extreme isoelectric points (Cordwell, 2006 ).
An important point for the identification of vaccine candidates by proteomic techniques is the isolation of surface proteins without contamination from other cellular fractions. A new approach that allows fast and consistent identification of proteins that are expressed on the bacterial surface has been recently published (Rodriguez-Ortega et al., 2006) . The technique, consisting of the surface digestion of live bacteria with different proteases and analysis by MS, identifies the so-called ''surfome.'' The major assumption of the protocol is that the proteolytic digestion is performed under conditions that maintain bacterial cell integrity minimizing contamination of the samples with cytoplasmic proteins. Therefore, proteins identified by MS are assumed to be surface located. However, the protocol is best fit to Gram-positive bacteria, because Gram-negatives are lysed releasing cytoplasmic proteins in the preparation. A different method has been set up for Gramnegative bacteria that is based on the use of outer membrane vesicles (OMV) Nouwens et al., 2000; Phadke et al., 2001) . OMVs can be analyzed by 2DE and protein spot identification by MS (Rodriguez-Ortega et al., 2006 ). An alternative method is the digestion of the OMV proteins followed by the separation and analysis of generated peptides by LC-MS/MS (Bagnoli and Rappuoli, 2010) .
In addition to surface exposed antigens, secreted proteins and toxins are also viable vaccine candidates. In order to identify secreted factors (the ''secretome''), the same techniques mentioned above have been applied to the analysis of bacterial culture supernatants (Ravipaty and Reilly, 2010) .
Structural biology
One of the major challenges of vaccinology is to predict the immunogenic potential of a given antigen. Structural biology has demonstrated that antibodies usually recognize OMICS-DERIVED VACCINESconformational epitopes that cannot be predicted by sequence analysis. Several studies have shown that protective epitopes can be identified by structural studies of antigen-antibody complexes (Bizebard et al., 1995; Dormitzer et al., 2008; Gulati et al., 2002; Hewat et al., 1998) . Furthermore, 3D structure studies could be an important tool for predicting epitopes, which can be used in new vaccine design. Since the structures of myoglobin and hemoglobin by Kendrew and Perutz provided the first insights into the protein architecture and chemistry more than 50 years ago (Kendrew and Perutz, 1948) , the field of structural molecular biology has experienced extraordinary progress. Advances in crystallography and NMR techniques in the last decades has led to large and unprecedented protein structure databases, and now more than 55,000 protein structures have been deposited into the Protein Data Bank. The major technical improvements that allowed such an advance, include high-throughput robotic crystallization systems, cryo-crystallography, high energy synchrotrons, structure phasing approaches using anomalous signal, more powerful NMR magnetic fields, and advancement in software for crystallographic data collection, structure determination, and refinement ( Joachimiak, 2009 ). This wealth of protein structural data facilitated the birth of structural vaccinology, which aims to understand and correlate the immunological relationships between proteins and epitopes with protein tertiary structure but not necessarily with sequence homologies. In this way it is possible to optimize vaccine antigens by genetic engineering. For example, antigens can be engineered to expose predicted conformational epitopes, increase conformational stability, increase breadth of protection, improve the safety profile, and elimi- 
Part 3: Immunomics-Based Antigen Selection Approaches
Antigenomics
Antigenomics is a novel approach that combines the power of full genome coverage and serological antigen identification (Meinke et al., 2005) through the use of comprehensive smallfragment genomic-surface display libraries and human sera as selection agents. The antigenomic approach has been applied to antigen identification in several bacterial pathogens of the genera Staphylococcus and Streptococcus (Etz et al., 2002; Giefing et al., 2008) . Because humoral immunity is the cornerstone of protection against extracellular bacteria, antigens recognized by serum antibodies induced by pathogens may represent good vaccine candidates. In order to select vaccine candidates, either uniformly small (linear epitopes) or uniformly medium-sized (potential conformational epitopes) peptides encoded by the bacterial genome are displayed on the surface of E. coli via outer membrane proteins (Henics et al., 2003) . The practical application of antigenomics was validated by Etz and colleagues (2002) in order to identify vaccine candidates of S. aureus. Another example of the application of antigenomic analysis was for the identification of H. pylori vaccine candidates (Meinke et al., 2009 ). Using human convalescent sera from well-characterized donors, authors identified 124 annotated ORFs and 54 nonannotated peptides as antigens. The list comprised five proteins that were previously shown to confer protection in animal models, GroEL, UreB, CagA, catalase, and VacA (Ghiara et al., 1997) . Cytotoxin-associated gene A (CagA) (Bagnoli et al., 2005 ) and the vacuolating cytotoxin gene A (VacA) (Malfertheiner et al., 2008) , probably the two most studied vaccine candidates of H. pylori, scored very high in an antigenomic assay, suggesting that this technology is well suited to identify relevant protective candidates. Most recently, an antigenomics approach was also used for identification of potential antigens of Wang et al. (2010) .
Protein microarray
Protein and antibody microarray technologies are, in addition to antigenomics, 2D gel electrophoresis and mass spectrometry, two of the most promising technologies for immunomics studies.
In several recent publications, the possibility of using protein microarray technologies to identify novel potential diagnostic markers and/or vaccine candidates was explored. In particular, antigen microarrays (a type of analytical microarray) commonly used to detect antibodies in biological fluids (e.g., serum, saliva, blood) and define immunological profiles in specific diseases, can supply important information for vaccine discovery. Moreover, the technology can also be used to analyze antibody responses induced by vaccination and to map fragments or epitopes relevant to protective immunity against a given pathogen. Recently, a variety of microarrays containing either whole cells (mammalian cells, yeast, bacteria), phages, or purified biomolecules (e.g., purified proteins, lipids, carbohydrates, and linear peptides) have been developed (Li et al., 2003; Sartain et al., 2006; Steller et al., 2005) .
Antigen microarray technology was originally applied to the investigation of genetic phase variation in pathogens by Steller et al. in 2005 . The authors were able to express and purify 67 of 102 known phase-variable genes from MenB strain MC58 as recombinant proteins in E. coli. The microarray was later screened using 20 sera of patients convalescing from meningitis in comparison to 20 sera from healthy controls. A number of disease-specific antigens were identified which may have medical and diagnostic potential as disease markers.
Recently, Sartain et al. (2006) fabricated a protein microarray for the sero-diagnosis of M. tuberculosis. The arrays were constructed on FAST slides using native protein mixtures from M. tuberculosis cytosol and culture filtrates, isolated by multidimensional protein fractionation. The availability of such arrays allowed the authors to characterize the humoral immune response profiles common to individuals exhibiting various forms of tuberculosis, but also to address differences in the patterns of antigens recognized. Moreover, they identified four novel B cell sero-diagnostic targets (BrfB, LppZ, SodC, TrxC), which had not been previously detected by other methods.
In another recent publication, Bombaci et al. (2009) generated a Group A Streptococcus (GAS) antigen array, by spotting 102 different proteins, to investigate the relationship between the antibody response against GAS antigens and the TIC neurologic disorder. This study established for the first time a clear temporal correlation between the TIC syndrome and the immunological profile to GAS. Moreover, knowledge of 554 BAGNOLI ET AL.
antigens recognized by TIC sera with a high frequency could be important for the diagnosis of this particular neurologic disorder.
Part 4: Safer and More Efficacious Vaccines to Meet Global Health Needs
Vaccinomics and tailored vaccines
Vaccines have always been designed from the microbiology perspective. However, human genomics should also have a role in vaccine design. The application of pharmacogenomics to vaccines has led to a new science of vaccinomics (Poland, 2007) . Vaccinomics refers to the investigation of heterogeneity in host genetic markers at the individual or population level that may result in variations in immune responses to vaccines, with the hope of predicting and optimizing vaccine outcomes (i.e., maximizing the appropriate immune responses and minimizing vaccine failure and adverse events). One of the most interesting applications of vaccinomics is the twin studies. Differences in immune responses between monozygotic twins, can be attributed to differential environmental exposures, while variability within dizygotic twins are most likely to be caused by the different genetic backgrounds. An example of such a study was conducted to determine the genetic influence on variability in the immunological response to measles, mumps, and rubella viruses (Tan et al., 2001) . These data suggest that the genetic background of the host may play a substantial role in immunological response to measles vaccination, but a less important role to mumps and rubella vaccination. Another application of vaccinomics includes correlation studies between HLA class and MMR (measles, mumps, and rubella) vaccine outcomes (Poland et al., 2009) . Altogether, vaccinomics studies are showing that human genetic heterogeneity may result in different responses to vaccines. Understanding how vaccines affect gene transcription, regulation or expression, and thereby influence immune responses in different individuals, should improve vaccine efficacy and safety, and potentially provide tailored vaccines.
The biochemistry of vaccines
As described in the previous paragraphs, several types of techniques are available for the identification of vaccine candidates. Once the genes are selected they are often expressed in E. coli expression systems usually as His-Tag or GST-Tag fusions in order to facilitate subsequent purification steps. The affinity purified proteins are primarily used for immunological studies, in order to verify their ability to elicit in vivo immunoresponses. The current technology is such that the entire cloning, expression, and purification process can be remarkably fast, especially because many of the steps can be assigned to robotic stations that operate in a fully unmanned and independent manner (Grandi, 2001) . Once the best candidates are selected based on their in vivo activities, they are purified in a tagless form to a required purity, which is generally >90% and their physicochemical properties are assessed. Although the preferred products are the ones that are expressed intracellularly in a soluble form, some proteins that are produced insolubly in inclusion bodies may be rendered soluble by expressing them intracellularly in E. coli overexpressing bacterial chaperones (Amrein et al., 1995) or the inclusion bodies can be solubilized with chaotropic agents and subsequently refolded in vitro. Refolding processes, however, can be time consuming and expensive, depending upon whether or not the protein of interest has a tendency to aggregate during refolding, so efforts are being made to improve yields and refolding by optimizing process variables. Another strategy to obtain correctly refolded proteins is to have them secreted in E. coli, yeast, or CHO cells (Hart et al., 1994) .
The efficiency and consistency of a biopharmaceutical purification process determines drug quality, including which specific types and concentrations of residual host cell or process contaminants may remain. Purified protein antigens are therefore analyzed for their purity (i.e., for the presence of E. coli protein contaminants), and for their integrity (i.e., for variations in glycosylation, amino-terminal and carboxy-terminal sequence alterations, unnatural or incomplete disulfide bond formation, partial proteolysis, oxidation, or deamidation of amino acids). In order to detect host cell protein (HCP) contaminants, immunoassays using antisera against whole cell extracts of the expression system are used in the purification process. Purity and integrity are also monitored by reverse phase chromatography, analytical gel filtration/ MALLS (multiangle laserlight scattering), as well as mass spectrometry analysis.
Another point worthy of consideration is the presence of host cell endotoxin in the final vaccine preparation. Endotoxins are lipopolysaccharides (LPS) composed of a hydrophilic polysaccharide moiety, which is covalently bound to a hydrophobic lipid moiety linked to the bacterial cell wall of Gram-negative bacteria. They are a natural component of most expression systems used for production of therapeutic proteins. Endotoxins are released in the medium during growth, division, and cell death, and they are found almost everywhere during downstream recombinant protein purification from E. coli. Through the induction of proinflammatory cytokine secretion by monocytes, endotoxins may elicit a variety of effects, such as inflammatory reactions, shock, and tissue injury. Vaccines are not required to adhere to endotoxin levels as outlined in the United States Pharmacopoeia (USP). Vaccine manufacturers have to show that the vaccine is safe and efficacious in clinical trials. This is because for many of the vaccines on the market at the present, such as whole cell vaccines, it is impossible to discriminate reactogenicity due to endotoxin, from the many other components of the vaccine. However, we believe that in omics-derived vaccines, endotoxin levels should be closely monitored in order to decrease the reactogenicity of the vaccine (Brito and Singh, 2011) . Endotoxins are temperature and pH stable, and their removal is therefore a difficult task during protein purification (Sharma, 1986) . A general method for the removal of endotoxins from protein preparations is not available (Petsch and Anspach, 2000) , but various approaches are utilized, mostly depending on the nature of the protein to be purified. Among them, ionexchange chromatography (Mitzner et al., 1993; Weber et al., 1995) , affinity adsorbents such as immobilized L-histidine (Matsumae et al., 1990) , polymyxin B (Anspach and Hilbeck, 1995) , gel filtration chromatography, sucrose gradient centrifugation, and Triton X-114 phase separation (Aida and Pabst, 1990; Liu et al., 1997) .
Novel adjuvants
Most traditional vaccine formulations contain inactivated pathogen, killed pathogen, or pathogen-secreted toxins. Although there has been great success using these vaccines for some types of infectious diseases, there are many pathogens that are not amenable to such traditional approaches. Problems include inflammation and other unwanted host reactions, reversion to virulence, the inability to effectively culture the bacteria or virus, the possibility of inducing an autoimmune response, and the need for refrigerated storage (Babiuk, 1999; Levine and Sztein, 2004) . For these reasons, there has been a shift toward developing subunit vaccines that contain short, specific fragments of a pathogen that are noninfectious because they lack any potential to replicate in the host. This rational approach to vaccine design can create vaccines that are generally safer and more immunologically defined compared with the traditional empirical approaches. It must be highlighted that the acceptable safety profile is different in the case of therapeutic or prophylactic vaccines. In most cases preventive vaccines are given to a large number of healthy children in the first years of age; therefore, they have to be extremely safe and well tolerated. Subunit vaccine antigens are usually better tolerated compared to inactivated or liveattenuated pathogens; however, they are in general less immunogenic and often require the addition of an adjuvant (from the Latin adjuvare, meaning to help) to achieve protective immune responses.
The earliest definition of vaccine adjuvants describes them as components that are added to vaccine antigens to make them more immunogenic. Thus, an adjuvant is anything that can increase the immune-stimulatory behavior of an antigen and function in a number of ways, facilitating targeting of the antigen to immune cells, enhancing phagocytosis, providing an antigen depot for increased uptake by antigenpresenting cells (APCs), shielding antigen from rapid degradation, increasing the antigen half-life, and/or by directly activating pattern-recognition receptors (PRRs) on APCs (Gupta and Siber, 1995; Reddy et al., 2006) . All of these mechanisms involve stimulating APCs directly or indirectly, especially dendritic cells (DCs) (Iwasaki and Medzhitov, 2004) .
Several attempts have been made to group adjuvants into classes, to try to better define how they work. For example, a broad range of adjuvants have been grouped as ''delivery systems,'' which means that their predominant mechanism of action was thought to be the delivery of antigens to immune cells (O'Hagan and Valiante, 2003) . Thus, delivery systems present vaccine antigens to the immune system in an optimal manner, including controlled release and depot delivery systems, to increase the specific immune response to the antigen, and can also serve to deliver immunostimulants. Examples include: mineral salts (aluminium) (Lin et al., 2008) , emulsions (Montanide) (Miles et al., 2005; Peter et al., 2001 ) and MF59 (de Bruijn et al., 2007; O'Hagan, 2007) , virosomes (Cavanagh et al., 2008; Li et al., 2007) and liposomes, biodegradable polymeric microparticles, and immune-stimulating complexes (ISCOMs).
In addition, an alternative range of adjuvants have been described as ''immune potentiators,'' because they exert direct effects on immune cells, leading to their activation (O'Hagan and Valiante, 2003) . Examples include Toll-like receptor (TLR) agonists such as monophosphoryl lipid A (MPL) (Garcon etr al., 2006) , cytokines [granulocyte-macrophage colonystimulating factor (GM-CSF), IL-2, IFN-g, and Flt-3), saponins, and bacterial exotoxins (cholera toxin and heat-labile toxin).
However, this classification system, which was always overly simplistic, has been largely superseded by recent observations, that highlighted that delivery systems can also act as immune potentiators (Mosca et al., 2008; Seubert et al., 2008) .
Until today few vaccine adjuvants have been licensed for use in human. Among them alum (aluminum salts) has been widely used for more than 70 years, and until recently represented the only adjuvant approved in the United States. Oil in water emulsions (MF59 and AS03) are licensed for adjuvanted influenza vaccines in Europe. AS04, a combination adjuvant composed of MPL adsorbed to alum is approved for hepatitis B virus (HBV) and human papillomavirus (HPV) vaccines in Europe and has been recently licensed in the USA (O'Hagan and De Gregorio, 2009 ). Other adjuvants approved in human vaccines are virus-like particles (self-assembling particles composed of one or more viral proteins), immunopotentiating reconstituted influenza virosomes (registered as a component of the hepatitis A vaccine in Europe, Asia, and South America) (Mbow et al., 2010) .
Discovery and development of new adjuvants is essential because the few currently approved vaccine adjuvants do not always induce the desired protective and sustained immune response against different target pathogens. For instance, there is an acute need to develop effective and safe vaccines against important infectious diseases including HIV, malaria, and tuberculosis, and significant challenges remain in terms of improving the effectiveness of prophylactic vaccines and developing therapeutic vaccines against important infectious diseases, cancer, and Alzheimer's disease. Additionally, the identification of vaccine adjuvants that can help to elicit a broad and sustained immune response in immunologically hyporesponsive populations such as the elderly, immunocompromised, and the pediatric populations is urgently needed. Further benefits in identifying effective and safe adjuvants encompass antigen dose sparing and a means to shift the immune response toward a specific T-cell phenotype (Th1, Th2, or Th17) to mount the appropriate response against defined pathogens (Mbow et al., 2010) .
With a growing knowledge of the immunological mechanisms of adjuvant action, including identifying the roles of specific signaling pathways important in regulating adaptive immunity, and of antigen recognition, processing and presentation, there has been a recent renaissance in vaccine adjuvant research. Novel vaccines will become increasingly more tailored and therefore more effective therapeutics. The challenge will be to find the balance between effective immune stimulation and potentially excessive inflammatory responses and in sculpting adaptive immunity to achieve the desired outcomes to vaccination in preventing and treating infectious, chronic diseases and cancer (Iwasaki and Medzhitov, 2010) .
A recurrent theme in recent vaccine adjuvant research is to trigger adaptive, antigen-specific responses by first stimulating the innate immune system, and particular attention is given to the incorporation of TLR agonists. The next generation of vaccines will largely be designed to deliver defined highly purified antigens, target DCs (e.g., by size or receptor binding) and/or potentiate antigen immunogenicity via TLR agonists. Combining particulate delivery systems with TLR agonists will most likely be most effective. Novel vaccines in the future could contain multiple TLR combinations and other PRR agonists in order to take advantage of their synergistic effects on cytokine production in enhancing immune responses (Black et al., 2010) .
With recent advances in the fields of immunology, genomics, proteomics, vaccinomics, and the Human Genome Project several novel candidate subunit vaccines are under investigation for clinical applications ). The goal of pharmacogenomics and vaccinomics is to identify human genetic variants that predict adverse responses to vaccines, predict aberrant immune responses, contribute to tailored therapy, and that predict susceptibility to diseases and response to vaccines (Meyer, 2004) . Vaccinomics may also be useful in the development and use of existing and novel vaccine adjuvants and stimulants. For example, specific polymorphisms are associated with significantly diminished humoral and/or cell-mediated immune responses (Dhiman et al., 2007 (Dhiman et al., , 2008 . Understanding the mechanism by which such polymorphisms diminish innate and other immune responses may offer a critical insight into designing work around the limitations imposed by such polymorphismseither by developing new adjuvants that utilize other receptors, or by the addition of stimulant molecules that can potentiate or augment the immune response.
Despite significant ongoing concerns, the necessary safety data is now available to show that new generation adjuvants can be safely used in diverse human populations. In combination with data showing the positive contributions of the adjuvants to the immune response, this safety data should allow several vaccines containing novel adjuvants to obtain licensure within the next few years. This implies also improved preclinical models and progress during the development phase and manufacturing process.
A comprehensive evaluation of all of the latest designs will be the next step to significantly advance adjuvanted vaccines to the next level. Similarly, systematic studies are needed that define which combined properties form the safest and most effective future vaccines.
The role of public health and regulatory bodies in the omics revolution National regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are tasked with ensuring the safety, purity, and potency of new medical products including vaccines prior to entering the market. To fulfill their mission, both the FDA and the EMA rely heavily upon the best current scientific knowledge and practice. Benefits realized by the rapid developments in omics sciences are not restricted to discovery and development in vaccine science as discussed above, but extend to the attendant regulatory science intended to ensure vaccine safety and efficacy. One illustrative example is that of toxicogenomics whose underlying principle is that compounds with similar mechanisms of toxicity and efficacy will have similar gene expression profiles (Gomase and Tagore, 2008; Ryan et al., 2008) . Through a better understanding of both the compounds' mechanisms of action and their toxicity, toxicogenomics may facilitate the identification of genetic biomarkers predictive of potential adverse events (AEs) associated with new vaccines.
The omics revolution has the potential to identify safety issues early on in vaccine development, streamlining clinical testing and decreasing the exposure of human subjects to potentially unsafe products. The omics sciences thus hold great promise in addressing some of the gaps in regulatory science that often limit comprehensive regulatory reviews of the new generation of vaccines. These include gaps in the ability to extrapolate animal data to humans, the paucity of validated biomarkers for predicting AEs, the difficulty of evaluating genetic and carcinogenic risks, and insufficiently characterized gender-and population-specific immune responses.
Although the regulatory authorities have generally embraced these novel technologies, they may have limited experience in reviewing data for products developed using them, and are encumbered by the current dearth of studies specifically aimed at regulatory science. Nonetheless, in a commendable response to the ongoing omics revolution, regulatory authorities have begun to provide guidance intended to facilitate the integration of pharmacogenomics and pharmacogenetics studies into global drug development. Several recent guidances and ''concept'' articles have been released by the ICH and both the EMA and FDA (http:// www.ema.europa.eu/ema/index.jsp?curl ¼ pages/regulation/ general/general_content_000411.jsp&murl¼menus/regulations/ regulations.jsp&mid¼WC0b01ac058002958e&jsenabled¼true; http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm; http://www .ich.org/products/guidelines.html) designed to facilitate transitions from pharmacogenomics biomarker discovery, through nonclinical studies, and finally to clinical phases of drug development. Perhaps the most significant positive step forward in filling the gaps in regulatory science detailed above was the creation of the FDA's Critical Path Initiative to ensure that advances in treatment such as those based on omics actually do materialize (Woodcock and Woosley, 2008) . The intent of the initiative is to facilitate the collaborative development of these tools and processes through consortia of industry, academic and regulatory scientists that share resources, expertise, and experience in a precompetitive environment. The European Innovative Medicines Initiative (EIMI) was launched with similar goals (Kamel et al., 2008) .
As exemplified by the recent global experience with the A (H1N1) flu pandemic, there has been a deterioration of public trust in both vaccine manufacturers and public health authorities. In the current atmosphere of mistrust and suspicion, perceived risks of vaccination begin to outweigh risks of vaccine-preventable disease as the public turn to multiple, and often questionable, sources of information. Complicating issues further are the recent and legitimate arguments that developments in genomics and genetic testing may lead to discriminatory practices in the workplace (i.e., genetic discrimination) (Silvers and Stein, 2003) . One major challenge that the public health and regulatory bodies will continue to face in the effort to establish and maintain public trust is finding the appropriate balance between facilitating the promise of innovative vaccine development that the omics technologies bring on the one hand, and applying stringent, science-based regulatory oversight that ensures adequate safety on the other hand. If the new technologies are to deliver OMICS-DERIVED VACCINESon their potential, both the public and health care providers will need to be properly educated. This task falls upon not only regulatory bodies, but extends to industry, academic institutions and health professionals and their associations themselves if the knowledge transfer is to be truly successful. Regulatory authorities would be well advised to initiate more active public outreach programs that facilitate a greater degree of transparency in the review process and the outcomes of that process. In addition, the strengthening of regulatory authority internal competency in the new technologies, and the allocation of resources as well as the leveraging of current funding opportunities (such as Critical Path and the EIMI) in the regulatory sciences should help regain public acceptance of the new technologies and products and hopefully, a renewed trust in public health authorities and the private industries they regulate. Despite the great promise omics technologies have in facilitating vaccine development, their true potential will remain theoretical if the global inequities in vaccine availability are not fully addressed. Although vaccine access and uptake are reliable and rapid in industrialized nations where disease burden is relatively low, uptake has been achingly slow in the world's least developed nations where disease burden is high and immunization could constitute the most cost-effective intervention to save the lives of multitudes of young children. Concerted global efforts such as the Global Alliance for Vaccines and Immunization (GAVI) and the United Nations Millennium Development Goals have been created to ameliorate this harsh reality. GAVI has identified vaccine access, equity, and lack of investment as the three fundamental gaps. Nonetheless, obstacles preventing global mass vaccination are complex and may not be overcome solely by economic measures (Levine et al., 2010) . Perhaps the area in which omics technologies and their products may best enhance equity is in improving vaccine delivery (Levine and Robins-Browne, 2009 ). Technologies that improve vaccine thermostability, maintain potency (improved immunogenicity and/or reduced dosing through novel adjuvants and vector systems), and provide novel administration routes (orally, mucosally, or transcutaneously using needle-free devices) may collectively improve delivery and uptake in impoverished areas of the world.
Conclusions
Availability of the complete set of pathogens' genes, proteins, and their expression profiles has always been perceived as a tremendous source of information for vaccinology. However, the challenge is to understand how we can extrapolate useful information from ''omes'' and apply it to vaccine discovery and development. Initially, approaches were mainly based on genomics and proteomics. In the year 2000, an article describing the selection of vaccine candidates against serogroup B meningococcus by whole-genome sequencing was published (Pizza et al., 2000) . The approach was termed reverse vaccinology because antigens were selected prior to experimental testing (Rappuoli, 2000) . Following genome-based approaches, other vaccine discovery strategies emerged. Techniques based on immunomics, such as the socalled antigenomics can identify candidates expected to be immunogenic in humans. Approaches based on transcriptomics or proteomics are able to identify candidates expressed by pathogens under different growth conditions (Table 1) . Studies done to date using different approaches have generally shown a significant degree of overlap. Importantly, recent studies based on proteomics showed that group B and A streptococcal antigens, predicted by in silico analysis, were confirmed to be expressed and exposed on the surface of bacteria. Other examples, which showed a good The study of functional and dynamic aspects of genes through mutagenic and transcriptomic analyses Genomics
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overlap include studies on S. aureus done by antigenomics and reverse vaccinology (Etz et al., 2002; Stranger-Jones et al., 2006) and studies on antigen selection against serogroup B meningococcus by reverse vaccinology (Pizza et al., 2000) or by transcriptomics (Grifantini et al., 2002) . However, despite a large overlap of results obtained with the different techniques, there were a number of candidates that appeared to be approach-specific. Therefore, the outcome of the different approaches is not completely redundant, and each of them can supply different information. For example, proteomics is able to confirm expression and location of antigens selected by in silico analysis (Doro et al., 2009) , while antigenomics provides important information about pre-existing human immunity (Meinke et al., 2005) . On the basis of these observations, we could assume that the most reliable selection strategy is a combination of the different approaches. In our experience this approach has shown to be efficacious and from the first project, which was based entirely on in silico prediction using one genome (Pizza et al., 2000) , we have added additional selection criteria including comparative genomics and proteomics (Maione et al., 2005) , functional genomics (Grifantini et al., 2002) , and immunomics (Bombaci et al., 2009) . Therefore, we believe that given the wealth of information accumulated in omics databases and the availability of faster and cheaper highthroughput technologies (e.g., DNA sequencing and microarray, mass spectrometers), vaccine research has the opportunity to become a truly omics-based science. That does not mean that vaccinology needs to change its principles and criteria. Indeed, the guiding concept of reverse vaccinology is the same as when it was invented: rational prediction of antigens most likely to be encountered by the host immune system (surface and secreted proteins). What changes is the source of data: from one genome to multiple genomes and all other omes relevant for vaccine discovery. In addition to the improvements in discovery approaches, today's vaccines are expected to be better characterized, with improved safety profiles and efficacy in a broader range of individuals (including immunocompromised patients and the elderly) compared to older vaccines. Concerning safety, antigens can be engineered to impair toxic activity or eliminate any homologies with human antigens. Protein purification is performed ensuring that only minimal traces of contaminants are present in the final product. During this step, proteins are fully characterized with a number of techniques that may include RP-HPLC, SEC-HPLC, MS, SDS-PAGE, and crystallography. Target populations of several vaccines in development may have stringent efficacy requirements. If a vaccine is administered to immunocompromised, elderly, or cancer patients it is likely that the implementation of novel improved adjuvants will be of critical importance.
Despite the progress made in the last decade, we cannot yet say that we have reached the point of a true rational design of vaccines. Indeed, that goal is highly dependent on further experimental studies and empirical observations. This is true both for antigen prediction as well as for vaccine efficacy tests. Furthermore, efforts are still failing in the development of efficacious vaccines against several viruses. Viral antigen prediction is very simple because of the small number of genes present in viruses and lack of expression variability. However, the antigen sequence of many viruses is extremely variable and protective epitopes are difficult to identify. One solution to these issues may be based on structural biology studies. This is mainly due to the following reasons. Often, the first line of defense against pathogens is antibody-mediated protection. Structural biology has provided evidence bolstering the notion that antibodies generally recognize conformational epitopes that cannot be predicted by sequence analysis. Several recent studies have shown that protective epitopes can be identified by structural studies of antigenantibody complexes. These studies may provide the information necessary to develop vaccines against variable viruses as well as the first information to build prediction methods to identify protective epitopes.
Most licensed vaccines have been developed against pathogens that show limited antigenic variation (e.g., diphtheria, tetanus, HIB, polio, papillomavirus, HAV, HBV, MMR, and typhoid fever). On the other hand, vaccines against pathogens that display variable antigens and require T-cell immunity are still mostly lacking (e.g., serogroup B meningococcus, pneumococcus, group A and B Streptococcus, Chlamydia trachomatis, Staphylococcus aureus, parasite diseases, and malaria) (Rappuoli, 2007) . Omics-based antigen discovery approaches are showing promising results for most of these infectious agents and several candidates have been moved into clinical trials (Table 2) .
Globally, vaccination together with the wider availability of potable water, has had the most profound positive effect on the quality of public health of any measure: during the past century, these products essentially eliminated most infectious diseases causing mortality in infants and children. In August 2010 the 30th anniversary of smallpox eradication was celebrated (Enserink, 2010) . However, smallpox remains the only human disease to have been completely eradicated worldwide. Polio vaccination campaign, although extremely successful (99% reduction of cases reported in 20 years), has not yet met complete global eradication. Most cases of polio happen in developing countries, and this is just one example of the limitations that we have in delivering vaccines to poor countries. Excess mortality of children living in developing countries is largely due to vaccine-preventable diseases. Fortunately, important initiatives such as GAVI, the International Finance Facility for Immunisation (IFFIm) and the Advanced Market Commitment (AMC), are now aiding global health organizations to face this urgent need (Levine and Robins-Browne, 2009 ). Convergence of omics science applied to pathogens and vaccinology in parallel with more efficacious adjuvants and stable formulations can improve the success of vaccination campaigns in impoverished areas of the world. However, none of technical improvements or new discoveries discussed throughout this article can bridge the divide between scientists and society without the implementation of appropriate communication tools (Ozdemir et al., 2009) . A critical role in supporting scientific and technological advancement as well as in improving communication necessary to rebuild public trust in vaccines will be played by policymakers (Kolker, 2010) . Finally, the next challenge is to integrate human omics in vaccine discovery and development to more properly tailor vaccines to human immunological response as exemplified by the recent rise of vaccinomics (Poland, 2007) .
